Richard J Gregory

US Patent:

6358507, Mar 19, 2002

Filed:

Oct 12, 1999

Appl. No.:

09/416673

Inventors:

Johanne Kaplan - Sherborn MA
Donna Armentano - Belmont MA
Richard J. Gregory - Westford MA

Assignee:

Genzyme Corporation - Framingham MA

International Classification:

A61K 4800

US Classification:

424 932, 424 936, 4353201, 435 691, 435455, 435456, 435325, 435366, 435 911, 435 914, 435 9141, 435 9142, 435371

Abstract:

The present invention relates to transgene expression systems, related compositions comprising the transgene expression systems, and methods of making and using them. Preferred systems employ an adenovirus transgene expression vector comprising DNA encoding a transgene which codes for a desired product operably linked to expression control sequence, and at least a portion of the adenovirus E3 region and certain portions of the E4 region. The E4 portions comprise the open reading frame sequence known as E40RF3 and at least one other portion of E4. Preferably the E4 portion of the vector (or âE4 cassetteâ) includes E40RF3 and at least one other portion selected from E40RF4, E40RF6/7 and E40RF3/4. The invention has a number of important features including improving persistency of transgene expression in a desired host cell. The transgene expression systems of the present invention are useful for a variety of applications including providing persistent cellular expression of the transgene in vitro and in vivo.

US Patent:

6379927, Apr 30, 2002

Filed:

May 19, 1999

Appl. No.:

09/315113

Inventors:

Douglas Antelman - Encinitas CA
Richard J. Gregory - Westford MA
Kenneth N. Wills - Encinitas CA

Assignee:

Canji, Inc. - San Diego CA

International Classification:

C12P 2104

US Classification:

435 697, 530350, 5303871, 4241921

Abstract:

Fusions of the transcription factor E2F and the retinoblastoma protein RB are provided, along with methods of treatment of hyperproliferative diseases.

US Patent:

6432927, Aug 13, 2002

Filed:

May 26, 2000

Appl. No.:

09/579897

Inventors:

Richard J. Gregory - Westford MA
Karen Vincent - Arlington MA

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

A61K 3170

US Classification:

514 44, 4353201, 435325, 435 914, 435455, 536 234, 536 241, 424 932

Abstract:

The present invention provides recombinant nucleic acid molecules encoding a chimeric transactivator protein including a DNA binding domain of a DNA binding protein and a protein domain capable of transcriptional activation. The present invention also provides recombinant viral and non-viral vectors that are able to infect and/or transfect and sustain expression of a biologically active chimeric transactivator proteins in mammalian cells. Also provided are host cell lines and non-human transgenic animals capable of expressing biologically active chimeric transactivator proteins. In another aspect, compositions and methods for treating or preventing ischemic damage associated with hypoxia-related disorders are provided.

US Patent:

6485720, Nov 26, 2002

Filed:

Aug 8, 2001

Appl. No.:

09/924925

Inventors:

Johanne Kaplan - Sherborn MA
Donna Armentano - Belmont MA
Richard J. Gregory - Westford MA

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

A61K 4800

US Classification:

424 932, 424 931, 424 936, 4353201, 435455, 435456, 435457, 435 691, 435325, 435366

Abstract:

The present invention relates to transgene expression systems, related compositions comprising the transgene expression systems, and methods of making and using them. Preferred systems employ an adenovirus transgene expression vector comprising DNA encoding a transgene which codes for a desired product operably linked to expression control sequence, and at least a portion of the adenovirus E3 region and certain portions of the E4 region. The E4 portions comprise the open reading frame sequence known as E4ORF3 and at least one other portion of E4. Preferably the E4 portion of the vector (or âE4 cassetteâ) includes E4ORF3 and at least one other portion selected from E4ORF4, E4ORF6/7 and E4ORF3/4. The invention has a number of important features including improving persistency of transgene expression in a desired host cell. The transgene expression systems of the present invention are useful for a variety of applications including providing persistent cellular expression of the transgene in vitro and in vivo.

US Patent:

6902731, Jun 7, 2005

Filed:

May 19, 1999

Appl. No.:

09/315116

Inventors:

Douglas Antelman - Encinitas CA, US
Richard J. Gregory - Westford MA, US
Kenneth N. Wills - Encinitas CA, US

Assignee:

Canji, Inc. - San Diego CA

International Classification:

A01N063/00
A01N043/04
C12N015/00
C12N015/63

US Classification:

424 932, 424 931, 435 691, 4353201, 435325, 435455, 514 44

Abstract:

Fusions of the transcription factor E2F and the retinoblastoma protein RB are provided, along with methods of treatment of hyperproliferative diseases.

US Patent:

6989268, Jan 24, 2006

Filed:

May 19, 2003

Appl. No.:

10/441510

Inventors:

Richard J. Gregory - Carlsbad CA, US
Ken N. Wills - Encinitas CA, US
Daniel C. Maneval - San Diego CA, US

Assignee:

Canji, Inc. - San Diego CA

International Classification:

C12N 5/10
C12N 15/861

US Classification:

4353201, 435325, 435366, 424 931, 424 932, 424 936

Abstract:

This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with thymidine kinase metabolite in order to be effective).

US Patent:

7041284, May 9, 2006

Filed:

Oct 28, 1997

Appl. No.:

08/958570

Inventors:

Richard J. Gregory - Carlsbad CA, US
Ken N. Wills - Encinitas CA, US
Daniel C. Maneval - San Diego CA, US

Assignee:

Canji, Inc. - San Diego CA

International Classification:

A61K 48/00
C12N 15/861
C12N 15/63

US Classification:

424 932, 424 931, 424 936, 4353201, 435 691, 435455, 435456, 435325

Abstract:

This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine dinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective. ).

US Patent:

7053062, May 30, 2006

Filed:

Jul 3, 2002

Appl. No.:

10/190394

Inventors:

Richard J. Gregory - Westford MA, US
Karen Vincent - Arlington MA, US

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

A61K 31/70
C12N 15/00
C12N 15/63
C07H 21/04

US Classification:

514 44, 4353201, 435455, 536 234

Abstract:

The present invention provides recombinant nucleic acid molecules encoding a chimeric transactivator protein including a DNA binding domain of a DNA binding protein and a protein domain capable of transcriptional activation. The present invention also provides recombinant viral and non-viral vectors that are able to infect and/or transfect and sustain expression of a biologically active chimeric transactivator proteins in mammalian cells. Also provided are host cell lines and non-human transgenic animals capable of expressing biologically active chimeric transactivator proteins. In another aspect, compositions and methods for treating or preventing ischemic damage associated with hypoxia-related disorders are provided.